分组1 - MannKind reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, and an increase from $0.02 per share a year ago [1] - The company posted revenues of $76.78 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.48%, and up from $58.47 million year-over-year [2] - MannKind has surpassed consensus revenue estimates three times over the last four quarters [2] 分组2 - The stock has underperformed, losing about 12.1% since the beginning of the year, while the S&P 500 gained 1.3% [3] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $75.11 million, and for the current fiscal year, it is $0.23 on revenues of $329.64 million [7] - The Medical - Biomedical and Genetics industry is currently in the top 24% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]
MannKind (MNKD) Q4 Earnings Meet Estimates